Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 956-968

  Beji, Abdelhamid ^a   Horst, David ^b   Engel, Jutta ^c   Kirchner, Thomas ^b   Ullrich, Axel ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b Pathologisches Institut   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; HEREGULIN BETA 1; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN CACO 2; CELL STRAIN DLD 1; CELL STRAIN LOVO; CELL STRAIN T 84; CELL STRUCTURE; COLON CANCER; COLON TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; TIME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMANS; NEOPLASM INVASIVENESS; NEUREGULIN-1; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84857089651     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1186     Document Type: Article

References (51)

1. Grivas PD, Antonacopoulou A, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, et al. HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. Eur J Cancer 2007;43:2602-11. (Pubitemid 350103546)
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9. (Pubitemid 23167612)
4. Li FY, Lai MD. Colorectal cancer, one entity or three. J Zhejiang Univ Sci B 2009;10:219-29.
5. Fearon ER, Vogelstein B. Agenetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
6. Ilyas M, Tomlinson IP. Genetic pathways in colorectal cancer. Histopathology 1996;28:389-99. (Pubitemid 26157686)
7. Miyakura Y, Sugano K, Konishi F, Ichikawa A, Maekawa M, Shitoh K, et al. Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology 2001;121:1300-9. (Pubitemid 33140447)
8. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
9. Gervaz P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 2001;44:364-72; discussion 372-3.
10. Zimonjic DB, Rezanka L, DiPaolo JA, Popescu NC. Refined localization of the erbB-3 proto-oncogene by direct visualization of FISH signals on LUT-inverted and contrast-enhanced digital images of DAPI-banded chromosomes. Cancer Genet Cytogenet 1995;80:100-2.
11. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 1989;86:9193-7. (Pubitemid 20010391)
12. Plowman GD, Whitney GS, Neubauer MG, Green JM, McDonald VL, Todaro GJ, et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci U S A 1990;87:4905-9.
13. Soler M, Mancini F, Meca-Cortes O, Sanchez-Cid L, Rubio N, Lopez-Fernandez S, et al. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer 2009;125:2565-75.
14. Sithanandam G, Fornwald LW, Fields J, Anderson LM. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinomacell line A549. Oncogene 2005;24:1847-59. (Pubitemid 40462787)
15. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006;24:4317-23. (Pubitemid 46630790)
16. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 2008;14:5188-97.
17. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-7. (Pubitemid 36827302)
18. Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M, et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 1997;10:142-8. (Pubitemid 27110039)
19. Campbell MR, Amin D, Moasser MM.HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010;16:1373-83.
20. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, et al. Oncogenes and signal transduction. Cell 1991;64:281-302. (Pubitemid 121001255)
21. Kim HH, Sierke SL, Koland JG. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem 1994;269:24747-55.
22. Sithanandam G, Smith GT, Masuda A, Takahashi T, Anderson LM, Fornwald LW. Cell cycle activation in lung adenocarcinoma cells by the ErbB3/ phosphatidylinositol 3-kinase/Akt pathway. Carcinogenesis 2003;24:1581-92. (Pubitemid 37304663)
23. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005;1:2005.0008.
24. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL III. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 1994;91:8132-6.
25. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994;269:14661-5.
26. Carraway KL III, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, et al. The erbB3 gene product is a receptor for heregulin. J Biol Chem 1994;269:14303-6. (Pubitemid 24191194)
27. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995;14:4267-75.
28. van der Horst EH, Weber I, Ullrich A. Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma. Int J Cancer 2005;113:689-98. (Pubitemid 40101248)
29. van der Horst EH, Murgia M, Treder M, Ullrich A. Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. Int J Cancer 2005;115:519-27. (Pubitemid 40656708)
30. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41. (Pubitemid 46160912)
31. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45. (Pubitemid 17082655)
32. Choi S, Choi Y, Dat NT, Hwangbo C, Lee JJ, Lee JH. Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells. Cancer Lett 2010;293:23-30.
33. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65. (Pubitemid 36342255)
34. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. Trends Cell Biol 2006;16:443-52. (Pubitemid 44293399)
35. Liles JS, Arnoletti JP, Tzeng CW, Howard JH, Kossenkov AV, Kulesza P, et al. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol Ther 2010;10:555-63.
36. Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Filali-Mouhim A, Begin LR, et al. Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU Int 2007;100:303-9. (Pubitemid 47036584)
37. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009;33:2112-8.
38. Kapitanovic S, Radosevic S, Slade N, Kapitanovic M, Andelinovic S, Ferencic Z, et al. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 2000;126:205-11. (Pubitemid 30183023)
39. Baiocchi G, Lopes A, Coudry RA, Rossi BM, Soares FA, Aguiar S, et al. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis 2009;24:1059-68.
40. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-44. (Pubitemid 35175969)
41. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145-52. (Pubitemid 35175970)
42. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002;8:1153-60. (Pubitemid 35175971)
43. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB(Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45.
44. Soltoff SP, Carraway KL III, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994;14:3550-8. (Pubitemid 24160762)
45. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 30-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994;13:2831-41.
46. Fedi P, Pierce JH, di Fiore PP, Kraus MH. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 1994;14:492-500.
47. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009;37:217-22.
48. Lee D, Yu M, Lee E, Kim H, Yang Y, Kim K, et al. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest 2009;119:2702-13.
49. Thant AA, Wu Y, Lee J, Mishra DK, Garcia H, Koeffler HP, et al. Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells. Anticancer Res 2008;28:3579-92.
50. Li J, Hou N, Faried A, Tsutsumi S, Takeuchi T, Kuwano H. Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells. Ann Surg Oncol 2009;16:761-71.
51. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25. (Pubitemid 36929717)